



Company Overview

Heat Biologics is a biopharmaceutical company that develops immunotherapies with the goal of activating a patient's immune system against cancer through T-cell activation. Our proprietary, T-cell Activation Platform (TCAP) produces therapies designed to turn "cold" tumors "hot," and be administered in combination with checkpoint inhibitors and other immuno-modulators to increase effectiveness. We are currently enrolling patients in our Phase 2 clinical trial for non-small cell lung cancer, in combination with Bristol-Myers Squibb's nivolumab (Opdivo®). We also have numerous pre-clinical programs at various stages of development.

Heat Biologics to Present at 2021 BIO CEO & Investor Digital Conference

Feb 12 2021, 3:00 PM EST

Heat Biologics Announces Positive Interim Survival Data from Ongoing HS-110 Phase 2 Non-Small Cell Lung Cancer Trial

Feb 9 2021, 7:30 AM EST

Heat Biologics Announces Publication of Additional Preclinical COVID-19 Vaccine Results

Jan 27 2021, 7:30 AM EST

Stock Overview

Symbol	HTBX
Exchange	Nasdaq
Market Cap	180.62m
Last Price	\$7.91
52-Week	\$3.05 - \$30.11

03/04/2021 04:00 PM EST

Investor Relations

investorrelations@heatbio.com

Management Team

Jeffrey Wolf

Founder, Chairman and CEO

George Peoples, M.D., FACS

Chief Medical Advisor

Guillermo (Bill) Arana, MS

Executive Director, Clinical Development

William L. Ostrander

Chief Financial Officer

Gary Vinson

Vice President, Chemistry and Manufacturing Controls (CMC)

Cheni Kwok, Ph.D., CLP

Senior Business Development Advisor

Matthew M. Seavey, Ph.D.

Executive Director of Special Projects

Heat Biologics, Inc.

627 Davis Drive
Suite 400
Morrisville, NC 27560

Disclaimer

Except for the historical information contained here in, the matters discussed in this document are forward-looking statements that involve risks and uncertainties, including but not limited to business conditions and the amount of growth in our industry and general economy, competitive factors, and other risks detailed from time to time in the Company's SEC reports, including but not limited to its annual reports on form 10-K and its quarterly reports on Form 10-Q. The company does not undertake any obligation to update forward-looking statements. All trademarks and brand name are the property of their respective companies.